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Background: The aim of this study was to compare the efficacy and safety of once-
daily ciclesonide, a new-generation, on-site-activated, inhaled corticosteroid, with
once-daily budesonide in persistent asthma.
Methods: Eligible patients requiring budesonide or equivalent 320–640 mg
(ex-mouthpiece, equivalent to 400–800 mg; TurbohalerTM) daily entered a 2-week
baseline, and then a 2- to 4-week pretreatment period (budesonide 1280 mg/day; ex-
mouthpiece, equivalent to 1600 mg/day). Patients with an increase in forced
expiratory volume in 1 s (FEV1) of X7% or X0.15 L were randomised to ciclesonide
320 mg (ex-actuator, equivalent to 400 mg ex-valve) via a hydrofluoroalkane-metered
dose inhaler (HFA-MDI) without a spacer or budesonide 320 mg once daily in the
morning for 12 weeks. Change in FEV1 was the primary endpoint.
Results: In all, 359 patients were randomised. The FEV1 and forced vital capacity
(FVC) decreased by 0.18 and 0.12 L, respectively, in the ciclesonide group, and by
0.23 and 0.21 L in the budesonide group. For FEV1, ciclesonide was noninferior and
numerically superior to budesonide. For FVC, ciclesonide was statistically superior to
budesonide (P ¼ 0.010). Asthma symptom scores were comparable; the median
percentage of symptom-free days was significantly higher for ciclesonide (43.6%)
versus budesonide (25.8%) (P ¼ 0.017). Rescue medication use decreased signifi-
cantly only for ciclesonide patients (P ¼ 0.009). Frequency of adverse events was
low in both groups.Elsevier Ltd. All rights reserved.
656 4747; fax: +1 418 656 4762.
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L.-P. Boulet et al.786Conclusion: Ciclesonide 320 mg once daily by HFA-MDI without a spacer was at least
as effective as budesonide 320 mg once daily in persistent asthma.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are recommended as
first-line therapy for patients with persistent
asthma.1 However, some physicians as well as
patients are still concerned about the potential
local and systemic side effects associated with
these medications.2 Even though the currently
available ICS are effective and safe at the
recommended doses, development of a novel agent
with potent anti-inflammatory activity and an
improved safety profile is a welcome addition.3
Ciclesonide is an ICS administered as an inactive
parent compound that is converted to its active
metabolite, desisobutyryl-ciclesonide (des-CIC), by
esterase-mediated hydrolysis in the lung.4,5 The
active metabolite, des-CIC, has a 100-fold greater
relative glucocorticoid receptor binding affinity
than ciclesonide (relative glucocorticoid receptor
binding affinities are 1200 and 12, respectively;
dexamethasone reference is 100). In addition, des-
CIC undergoes extensive lipid conjugation that
creates an active drug reservoir ensuring prolonged
pulmonary residence time and continuous 24-h
anti-inflammatory activity ideal for once-daily
treatment regimens.6,7 Furthermore, des-CIC is
highly protein bound and rapidly metabolised,
leavingo1% of free drug in the systemic circulation
and potentially reducing systemic adverse
effects.7,8
The clinical efficacy and safety of ciclesonide
have been demonstrated in several studies. Cicle-
sonide has been shown to be effective at dose
ranges from 80 to 640 mg (ex-actuator, equivalent
to 100–800 mg ex-valve) once daily in maintaining
lung function in patients with mild-to-moderate
persistent asthma compared with placebo following
pretreatment with 400–1000 mg/day beclometha-
sone or equivalent.9,10 Ciclesonide has also been
shown to effectively reduce airway hyperrespon-
siveness to adenosine-50-monophosphate-induced
bronchoconstriction as well as early- and late-
phase allergen-induced asthmatic reactions.11,12
Moreover, ciclesonide 160 mg (ex-actuator, equiva-
lent to 200 mg ex-valve) administered once daily in
the morning or evening was shown to significantly
improve pulmonary function and control of asthma
symptoms.13
Ciclesonide is at least as effective as budesonide,
but has shown a superior safety profile in earlierpreclinical, anti-inflammatory studies.14 However,
there is no direct comparison of clinical profiles of
ciclesonide and budesonide using the same dose
and schedule. Therefore, the primary objective of
this study was to compare the efficacy and safety of
ciclesonide 320 mg (ex-actuator, equivalent to
400 mg ex-valve) with budesonide 320 mg
(ex-mouthpiece, equivalent to 400 mg; Turboha-
lerTM) once daily over 12 weeks.Methods
Patients
Eligible patients were between 12 and 75 years of
age with a diagnosis of persistent asthma for at
least 6 months as defined by the American Thoracic
Society criteria.15 Inclusion criteria to enter the
baseline period included a forced expiratory
volume in 1 s (FEV1) of 65–95% of predicted value
depending on pretreatment—the dose of ICS
(budesonide 320–640 mg or equivalent) and the
addition of other controller medications (long-
acting b2-agonists, leukotriene antagonists, or
equivalent).
Exclusion criteria included concomitant severe
diseases or contraindications for the use of ICS;
clinically relevant abnormal laboratory values
suggesting unknown disease; an asthma exacerba-
tion or infection of the lower airways within 4
weeks before entering the baseline period; and
emergency treatment or hospital admission for
asthma within 4 weeks before the baseline period.
Additional exclusion criteria included use of sys-
temic steroids within 4 weeks or injectable depot
steroids within 6 weeks before entering the base-
line period or more than three times during the last
6 months; evidence of chronic obstructive pulmon-
ary disease or other relevant lung diseases; heavy
smokers or ex-smokers (410 cigarettes/day or 42
pipes/day); suspected noncompliance; drug abuse;
or pregnancy.Study design
This was a multicentre, randomised, double-blind,
double-dummy, parallel-group study. The Ethics
Committee of each participating site approved
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informed consent. The study included three dis-
tinct periods: a 2-week baseline period, a 2- or
4-week pretreatment period (duration depending
on the response to budesonide administered during
the first 2 weeks), and a 12-week treatment period.
Patients had been maintained on a constant dose of
ICS that included budesonide 320–640 mg/day (ex-
mouthpiece or the actual dose delivered to the
patient from the Turbohaler mouthpiece, equiva-
lent to 400–800 mg; TurbohalerTM), fluticasone
propionate 176–440 mg/day (ex-actuator or the
actual dose delivered to the patient from the
outlet of the metred-dose inhaler (MDI), equivalent
to 200–500 mg ex-valve, the amount of drug
released by the valve of inhaler into the mouth-
piece), or equivalent for 4 weeks before baseline.
During the baseline period, all patients continued
their usual dosage of ICS and rescue medication as
needed, but all other anti-asthma controller
medications were not permitted. Subsequently,
patients entered the pretreatment period if they
had an asthma symptom score sum of at least four
or a total of eight or more doses of rescue
medication within 4 days before entry. Each patient
also had to have shown reversibility of FEV1X15% of
the initial value following 200–400 mg salbutamol
during or within 1 year before the baseline period;
diurnal peak expiratory flow (PEF) variation of
X15% for at least 3 days during the last 7 days of
the baseline period; or airway hyperresponsiveness
to methacholine or histamine (PC20 FEV1, p8mg/
mL) documented during or within 1 year before the
baseline period. All patients received budesonide
1280 mg daily (ex-mouthpiece, equivalent to
1600 mg; TurbohalerTM; four inhalations of 160 mg
(ex-mouthpiece, equivalent to 200 mg; Turboha-
lerTM) in the morning and four inhalations in the
evening) during the pretreatment period. The
pretreatment period with high-dose budesonide
was included in this study because patients were
still inadequately controlled with their current
therapy. Response to high-dose budesonide had to
be demonstrated; such a response would indicate
that ICS dose escalation would improve lung
function in the study population. Thus, patients
entering the treatment period had to fulfil inclusion
criteria and demonstrate improvement in FEV1
during the pretreatment period of either X7% or
0.15 L following the increase in their daily ICS dose
from 320–640 mg budesonide (or the equivalent) to
1280 mg budesonide. Furthermore, treatment with
high-dose budesonide before randomisation helped
to establish control of asthma symptoms and lung
function, which were then monitored for main-
tenance in the randomised treatment period.16,17Patients were randomised (using a computer-
generated list at a ratio of 1:1) to ciclesonide
320 mg (ex-actuator, equivalent to 400 mg ex-valve)
via a hydrofluoroalkane-MDI without a spacer or
budesonide 320 mg (ex-mouthpiece, equivalent to
400 mg; TurbohalerTM) once daily in the morning for
12 weeks. Salbutamol (100 mg/puff) served as
rescue medication for each patient throughout
the study.Patient assessments
Efficacy
The efficacy of ciclesonide and budesonide once
daily was determined by assessments of lung
function and control of asthma symptoms. The
change in FEV1 at the end of treatment was the
primary endpoint. The FEV1, forced vital capacity
(FVC), and morning and evening PEF were recorded
at each study visit according to American Thoracic
Society criteria.18 Salbutamol was withheld for at
least 4 h before each determination. For adults
(X18 years of age), predicted values were calcu-
lated according to the formula of the European
Community for Coal and Steel.19 For adolescents
(12–17 years of age), predicted values were
calculated according to previously published
values.20 All patients were given a mini-Wright
PEF meter and were instructed to read three PEF
measurements before rising in the morning and
between 6 and 8 p.m. each evening.
The parameters used to assess control of asthma
included asthma symptom scores; rescue medica-
tion use; number of asthma symptom-free days;
rescue medication-free days; and subjective effec-
tiveness rating by investigator and patient assess-
ments, made using the following rating scales: very
effective (good control of asthma), effective (not
optimal, but acceptable control of asthma),
slightly effective (only moderate control of asthma
symptoms, improvement desired), and ineffective
(poor control of asthma). Additionally, asthma
scores were recorded on a five-point scale as
follows: daytime asthma scores were recorded on
a scale from0 (very well, no symptoms) to 4
(asthma very bad, unable to carry out daily
activities as usual); night time asthma scores
ranged from 0 (no symptoms, slept through the
night) to 4 (bad night, awake most of the night
because of asthma). Patients also recorded the
number of inhalations per day of salbutamol rescue
medication.
The criteria satisfying lack of efficacy included a
clinical asthma exacerbation, defined as increasing
asthma symptoms and decrease in lung function
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decrease in morning PEF on 2 consecutive days by
430% below the baseline value); a decrease in
morning FEV1 of X20% of the prestudy value or
o50% predicted; a night time asthma score X2 on
at least four of the seven nights or X3 on at least
two of the seven days; a daytime asthma score of
X3 on at least four of the seven days directly
preceding a visit; or another deterioration in lung
function that compromised the patient’s health.Safety
All adverse events experienced by a patient or
observed by an investigator were recorded at each
study visit. All adverse events were classified as
mild, moderate, or severe, and were evaluated by
investigators for causal relationship to study med-
ication. A physical examination, including vital
signs and electrocardiogram, was performed at
the start of the baseline period and again at the
end of the treatment period. Additional routine
laboratory safety parameters included a haematol-
ogy and full chemistry panel (including hepatic and
renal function), urinalysis, and pregnancy test.Statistical analysis
All patients who received at least one dose of
ciclesonide were included in the intent-to-treat
(ITT) population, and patients who had no major
protocol violations were included in the per-
protocol (PP) population. Results obtained from
the PP analysis were confirmed by ITT analysis. The
primary endpoint was the noninferiority of cicleso-
nide 320 mg versus budesonide 320 mg administered
once daily in the morning based on the difference
in FEV1 from randomisation to the end of treat-
ment. The primary hypothesis for noninferiority
was tested using the 95% two-sided confidence
interval (95% CI) for differences between treatment
groups. Both PP and ITT analyses were performed
for noninferiority. Least-squares means and two-
sided 95% CI were presented for differences within
and between treatment groups. A sample size of
100 patients per treatment group was necessary to
ensure a power of 87% to establish a noninferiority
of ciclesonide 320 mg versus budesonide 320 mg
(noninferiority acceptance limit for the primary
efficacy variable FEV1 was set to 0.200 L). For all
endpoints except for the primary efficacy variable
FEV1, the ITT analysis is reported within text,
tables, and figures, unless there are relevant
differences in statistical results between the two
(ITT and PP) study populations, and PP analysis is
reported within the tables.All secondary variables were analysed in an
exploratory manner. Secondary variables FVC and
morning and evening PEF from diaries were
analysed analogously to FEV1 (noninferiority accep-
tance limits were 0.200 L; and to 25 L/min,
respectively). Changes in the sum of asthma
symptom scores and number of inhalations of
rescue medication between the week before the
last visit and the week before randomisation were
compared within treatments by Pratt’s modification
of Wilcoxon signed-rank test and between treat-
ments by Mann–Whitney U-tests. Between-treat-
ment comparisons for asthma symptom-free days,
rescue medication-free days, and patient-per-
ceived control of asthma symptoms (i.e., no
symptoms and no rescue medication use) were
analysed by Mann–Whitney U-tests. The primary
and secondary efficacy endpoints were evaluated
by analysis of covariance (ANCOVA).Results
Patient demographics and baseline disease
characteristics
A total of 688 patients were enrolled in the study
from 64 centres located in Canada, Hungary, Italy,
Poland, Portugal, and Spain, and 359 patients (ITT
population) were randomised to treatment (179 to
ciclesonide, 180 to budesonide). Of the 359
patients randomised to the two treatments, 320
patients were without protocol violations during
the study and represented the PP population. The
demographic and baseline disease characteristics
were similar between the two treatment groups
(Table 1). The majority of the randomised patients
(343 out of 359) were Caucasian.
Pulmonary function
During the pretreatment period with budesonide
1280 mg daily, mean FEV1 levels increased by 0.352 L
for the ciclesonide group (from 2.53 to 2.88 L) and
0.319 L for the budesonide group (from 2.42 to
2.74 L). After patients were randomised to either
ciclesonide 320 mg or budesonide 320 mg once daily,
FEV1 decreased by 0.18 and 0.23 L, respectively,
over 12 weeks of treatment (Po0.0001; PP analysis
of within-treatment comparison; Table 2). Cicleso-
nide was noninferior to budesonide with regard to
maintenance of FEV1 (95% CI ¼ 0.015, 0.121
for ciclesonide versus budesonide; PP analysis;
Table 2). Similar results were obtained by
ITT analysis (Fig. 1). There were no significant
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Table 1 Demographic and baseline characteristics (n ¼ 359).
Characteristics CIC 320 mgy OD (n ¼ 179) BUD 320 mgy OD (n ¼ 180)
Median age, years (range) 39 (12–72) 42 (12–71)
Sex (male), n (%) 79 (44) 69 (38)
Nonsmokers, n (%) 135 (75) 123 (68)
Smokers/ex-smokers, n (%) 44 (25) 57 (32)
Mean prestudy daily ICS dose, BDP equivalents (mg)z 740 767
Mean FEV1 (L7SD)
Start of 2-week baseline period 2.6070.73 2.4370.59
Start of pretreatment with BUD (1280 mg/day)y 2.5370.70 2.4270.60
Start of randomised treatment 2.8770.79 2.7470.66
Mean FEV1 (% predicted7SD)
Start of 2-week baseline period 8178 7977
Start of pretreatment with BUD (1280 mg/day)y 7878 7977
Start of randomised treatment 8979 9078
Reversibility change in FEV1 (%7SD)
y 21.179.1 23712.6
Mean morning PEF (diary) (L/min7SD)y 3827104 374799
Mean PEF variability (%7SD)y 6.775.2 6.075.0
CIC, ciclesonide; BUD, budesonide; OD, once daily; ICS, inhaled corticosteroid; BDP, beclomethasone dipropionate; FEV1, forced
expiratory volume in 1 s; SD, standard deviation; PEF, peak expiratory flow.
Intent-to-treat population.
yCiclesonide 320 mg is ex-actuator, equivalent to 400mg ex-valve; budesonide 320 and 1280 mg are ex-mouthpiece doses,
equivalent to 400 and 1600mmg (TurbohalerTM).
zPer-protocol population. Nineteen patients from the ciclesonide group and 20 patients from the budesonide group were
found to have major protocol violations. Thus, 160 patients from each treatment group made up the valid cases set for per-
protocol population analysis.
yStart of randomised treatment.
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with regard to change in FEV1 at the end of
treatment.
While mean FVC levels also decreased in both
treatment groups, the decrease in ciclesonide
patients (0.12 L; Po0.0001, within-treatment com-
parison) compared with that in budesonide patients
(0.21 L; Po0.0001, within-treatment comparison)
was significantly less (95% CI ¼ 0.02, 0.147;
P ¼ 0.011 for ciclesonide versus budesonide; ITT
analysis). Similar results were obtained after PP
analysis. For morning PEF, the least-squares mean
values over 12 weeks of treatment remained
virtually unchanged for the ciclesonide group
(–3 L/min; P ¼ 0.374), while there was a small
but significant decrease in the budesonide group
(10 L/min; P ¼ 0.007; ITT analysis) (Table 2;
Fig. 2). However, the differences between treat-
ment groups were not statistically significant. Mean
evening PEF levels did not significantly change from
the beginning of treatment for either ciclesonide or
budesonide treatment groups (P ¼ 0.50 and 0.179,
respectively). PP analysis of morning and evening
PEF measures yielded results comparable with the
ITT analysis.Asthma symptom scores and rescue
medication use
Although patients were treated with high-dose
budesonide (1280 mg daily) during the pretreatment
period, there were no significant differences
between the two treatment groups in median
asthma symptom score sums, night scores, and
daytime scores over the treatment period. How-
ever, the percentage of asthma symptom-free days
was 43.6% in the ciclesonide group compared with
25.8% in the budesonide group (Fig. 3). Addition-
ally, patients treated with ciclesonide experienced
a significant reduction in the median rescue
medication use over the course of treatment
(P ¼ 0.009) in contrast to no change in those
treated with budesonide (P ¼ 0.626), and there
was a corresponding significant difference bet-
ween treatment groups in median rescue medica-
tion use (P ¼ 0.026; Fig. 4). The median percen-
tage of rescue medication-free days, however,
was similar in both groups (57.5% versus 53.6%
for ciclesonide and budesonide group, respec-
tively). Similar results were obtained in the PP
analysis.
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Table 2 Change in lung function at the end of treatment.
Parameter PP ITT
CIC 320 mg OD BUD 320 mg OD CIC 320 mg OD BUD 320 mg OD
Spirometry
FEV1 (L)
Baseliney 2.91 2.74 2.86 2.75
Change versus baseliney –0.18 –0.23 –0.17 –0.22
P-value versus baseline o0.0001 o0.0001 o0.0001 o0.0001
Change versus BUDy 0.05 0.05
95% CI –0.015, 0.121 –0.007, 0.111
P-value versus BUD 0.125 0.087
FVC (L)
Baseliney 3.69 3.4 3.62 3.41
Change versus baseliney –0.12 –0.22 –0.12 –0.21
P-value versus baseline 0.0001 o0.0001 o0.0001 o0.0001
Change versus BUDy 0.1 0.08
95% CI 0.024, 0.172 0.02, 0.147
P-value versus BUD 0.01 0.011
Diary
Morning PEF (L/min)
Baseliney 388 372 382 373
Change versus baseliney –3 –11 –3 –10
P-value versus baseline 0.451 0.007 0.374 0.007
Change versus BUDy 8 6
95% CI –2, 18 –2, 15
P-value versus BUD 0.108 0.141
Evening PEF (L/min)
Baseliney 401 381 394 382
Change versus baseliney –1 –5 –2 –4
P-value versus baseline 0.833 0.16 0.5 0.179
Change versus BUDy 4 2
95% CI –4, 13 –6, 10
P-value versus BUD 0.331 0.591
PP, per-protocol; ITT, intent-to-treat; CIC, ciclesonide; BUD, budesonide; OD, once daily; FEV1, forced expiratory volume in 1 s;
CI, confidence interval; FVC, forced vital capacity; PEF, peak expiratory flow.
CIC 320mg is ex-actuator, equivalent to 400mg ex-valve; BUD 320 mg is ex-mouthpiece, equivalent to 400mg (TurbohalerTM).
yValues presented are means, paired values.
yValues presented are least-squares means.
L.-P. Boulet et al.790A total of 66 patients (18%) withdrew from the
study due to lack of efficacy in the ITT population.
In the budesonide group, there were more patients
(37 (21%)) than in the ciclesonide group (29 (16%))
that withdrew from the study due to lack of
efficacy. There were no significant differences
between treatment groups with regard to lack
of efficacy, physician assessments, or patient
self-assessments.Safety
During the double-blind treatment period, a total
of 168 (47%) patients experienced an adverseevent: 52% in the budesonide group and 42% in
the ciclesonide group (Table 3). Most adverse
events were mild or moderate in intensity and
considered ‘‘unrelated’’ or ‘‘unlikely related’’ in all
cases. Common adverse events in patients treated
with ciclesonide or budesonide included upper
respiratory infection (12% and 19%, respectively),
asthma (9% and 12%), bronchitis (3% and 3%),
pharyngitis (3% and 3%), rhinitis (2% and 3%), voice
alteration (2% and 1%), and sore throat (2% and 1%).
There were no cases of oral candidiasis in either
treatment arm.
Three patients experienced serious adverse
events: one patient in the ciclesonide group
(exacerbation of asthma), and two patients in the
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Figure 1 Time course of FEV1 during 12 weeks of therapy
with ciclesonide 320 mg QD and budesonide 320 mg QD.
Data are expressed as means7SD. FEV1, forced expiratory
volume in 1 s; QD, once daily; CIC, ciclesonide; BUD,
budesonide; and BID, twice daily. Ciclesonide 320 mg is an
ex-actuator dose, equivalent to 400 mg ex-valve; bude-
sonide 320 mg is an ex-mouthpiece dose, equivalent to
400 mg (TurbohalerTM).
Figure 2 Change from baseline in morning PEF with
ciclesonide 320 mg QD and budesonide 320 mg QD. Data
represent the intent-to-treat patient population and are
based on least-squares means. PEF, peak expiratory flow;
QD, once daily; CIC, ciclesonide; BUD, budesonide; and
BID, twice daily. Ciclesonide 320 mg is an ex-actuator
dose, equivalent to 400 mg ex-valve; budesonide 320 mg is
an ex-mouthpiece dose, equivalent to 400 mg (Turboha-
lerTM).
Figure 3 Percentage of patients with symptom-free days
based on the intent-to-treat population. Data are
presented as medians. CIC, ciclesonide; BUD, budeso-
nide; and QD, once daily. Ciclesonide 320 mg is an
ex-actuator dose, equivalent to 400 mg ex-valve; bude-
sonide 320 mg is an ex-mouthpiece dose, equivalent to
400 mg (TurbohalerTM). *P ¼ 0.018 versus budesonide.
Figure 4 Patients with rescue medication use over 12
weeks of treatment with ciclesonide 320 mg QD and
budesonide 320 mg QD. Data represent the intent-to-treat
patient population and are presented as medians. CIC,
ciclesonide; BUD, budesonide; and QD, once daily.
Ciclesonide 320 mg is an ex-actuator dose, equivalent to
400 mg ex-valve; budesonide 320 mg is an ex-mouthpiece
dose, equivalent to 400 mg (TurbohalerTM). *P ¼ 0.009
versus baseline; yP ¼ 0.626 versus baseline; and
zP ¼ 0.026 versus budesonide.
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Table 3 Frequently reported adverse events.
Patients, n (%)
CIC 320 mg OD (n ¼ 179) BUD 320 mg OD (n ¼ 180)
Total adverse events 75 (42) 93 (52)
Upper respiratory infection 22 (12) 34 (19)
Asthma 16 (9) 21 (12)
Bronchitis 6 (3) 6 (3)
Sore throat 3 (2) 2 (1)
Pharyngitis 6 (3) 5 (3)
Sinusitis 3 (2) 3 (2)
Rhinitis 4 (2) 6 (3)
Oral candidiasis 0 (0) 0 (0)
Voice alteration 3 (2) 2 (1)
Flu syndrome 7 (4) 12 (7)
CIC, ciclesonide; BUD, budesonide; OD, once daily.
Ciclesonide 320mg is ex-actuator, equivalent to 400 mg ex-valve; budesonide 320mg is ex-mouthpiece, equivalent to 400mg
(TurbohalerTM).
L.-P. Boulet et al.792budesonide group (carcinoma of the breast and
surgical repair of pre-existing ankle injury). There
were no clinically significant laboratory findings or
changes in vital signs in either treatment group.Discussion
The current study demonstrated that ciclesonide
320 mg once daily in the morning was at least as
effective as budesonide 320 mg once daily in
maintaining lung function and controlling asthma
symptoms in patients routinely requiring daily ICS
administration. Although differences were small,
the fall in FVC at the end of treatment was higher
in the budesonide group, and ciclesonide was more
effective in maintaining morning PEF. Moreover,
ciclesonide showed a significant reduction in rescue
medication use compared with budesonide.
Furthermore, both treatments showed a good
safety profile with low rates of adverse events.
Both ciclesonide and budesonide undergo rever-
sible conjugation with fatty acids in the airway and
lung.21,22 It is important to note that fatty acid
conjugation extends pulmonary retention time and
prolongs topical anti-inflammatory activity en-
abling once-daily treatment regimens.23 As a
consequence, both ciclesonide and budesonide
have shown efficacy when administered once
daily.13,24,25 In the present study, ciclesonide was
more effective than budesonide in maintaining lung
function and controlling asthma symptoms. This
observation may be related to the differences in
the physicochemical properties of ciclesonide andbudesonide. Although both corticosteroids form
lipid conjugates,21,26 lipid conjugates formed by
des-CIC are 5-fold more lipophilic than those of
budesonide.27 Therefore, the overall retention of
the lipid conjugates of des-CIC may be greater than
that of budesonide, thereby prolonging anti-inflam-
matory activity. Moreover, there are differences in
the formulation characteristics of budesonide
delivered via dry powder inhaler (Turbohaler) and
ciclesonide delivered via MDI. Consequently, the
lung deposition of ciclesonide inhaled via MDI is
50% of the delivered dose, which is higher than
the deposition that can be achieved by dry powder
inhalers.28,29
The study design involved a direct comparison
with an active comparator without a placebo arm.
Importantly, the target patient population included
patients routinely requiring daily administration of
moderate doses of ICS to control asthma symptoms.
Furthermore, both ciclesonide and budesonide
have been shown in earlier clinical trials to be
more effective than placebo in improving pulmon-
ary function and control of asthma symptoms in
patients with persistent asthma.9,30 The pretreat-
ment period of 2–4 weeks with budesonide 1280 mg/
day before randomisation was designed to deline-
ate the differences between the two ICS (cicleso-
nide and budesonide). As expected, following
randomisation to ciclesonide or budesonide, FEV1
decreased in patients treated with both study
medications, yet overall, each study drug was
comparable in maintaining adequate lung function
and control of asthma symptoms over 12 weeks.
These results support the findings in a previous
study where ciclesonide 80 or 320 mg once daily was
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equivalent to 200 mg; TurbohalerTM) twice daily in
improving lung function and control of asthma
symptoms.31
In conclusion, a once-daily morning inhalation of
ciclesonide 320 mg was at least as effective as
budesonide 320 mg in the treatment of persistent
asthma. Additionally, ciclesonide was statistically
superior to budesonide with regard to FVC, symp-
tom-free days, and rescue medication use. Both
agents were safe and well tolerated.Acknowledgements
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